Primary debulking surgery or neoadjuvant chemotherapy: what is the optimal treatment approach for obese patients with ovarian/fallopian tube/primary peritoneal carcinoma?

Worley, Michael

68 - Featured Poster
Primary debulking surgery or neoadjuvant chemotherapy: what is the optimal treatment approach for obese patients with ovarian/fallopian tube/primary peritoneal carcinoma?

Sunday, March 23, 2014: 1:01 PM

West Exhibit Hall (Tampa Convention Center)

M. J. Worley Jr.¹, S. Guseh¹, J. A. Rauh-Hain², K. M. Esselen¹, M. G. Muto¹, C. M. Feltmate³, R. S. Berkowitz¹, M. G. Del Carmen², J. O. Schorge² and N. S. Horowitz⁴
¹Brigham and Women's Hospital/Harvard University, Boston, MA, ²Massachusetts General Hospital/Harvard University, Boston, MA, ³Brigham and Women's Hospital and Harvard University, Boston, MA, ⁴Harvard University, Boston, MA

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

68 - Featured Poster
Primary debulking surgery or neoadjuvant chemotherapy: what is the optimal treatment approach for obese patients with ovarian/fallopian tube/primary peritoneal carcinoma?

68 - Featured Poster Primary debulking surgery or neoadjuvant chemotherapy: what is the optimal treatment approach for obese patients with ovarian/fallopian tube/primary peritoneal carcinoma?

68 - Featured Poster
Primary debulking surgery or neoadjuvant chemotherapy: what is the optimal treatment approach for obese patients with ovarian/fallopian tube/primary peritoneal carcinoma?